Sanofi, Regeneron Set to Improve Alirocumab Patient Affordability, Access in U.S.
Sanofi and Regeneron announced on Monday, Feb. 11 alirocumab will be made available at a reduced list price to help lower patient out-of-pocket costs and improve access.
This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
The new, lower-priced alirocumab is expected to be available for pharmacies to order in early March.
Click here to read the complete press release.